ELVAF
Price
$0.90
Change
-$0.05 (-5.26%)
Updated
Nov 8 closing price
Capitalization
9.63M
IBIO
Price
$3.37
Change
-$0.43 (-11.32%)
Updated
Apr 4, 02:40 PM (EDT)
Capitalization
37.43M
Ad is loading...

ELVAF vs IBIO

Header iconELVAF vs IBIO Comparison
Open Charts ELVAF vs IBIOBanner chart's image
Evolva Holding AG
Price$0.90
Change-$0.05 (-5.26%)
Volume$194
Capitalization9.63M
iBio
Price$3.37
Change-$0.43 (-11.32%)
Volume$1.2K
Capitalization37.43M
ELVAF vs IBIO Comparison Chart
Loading...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVAF vs. IBIO commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVAF is a Hold and IBIO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ELVAF: $0.90 vs. IBIO: $3.80)
Brand notoriety: ELVAF and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVAF: 100% vs. IBIO: 61%
Market capitalization -- ELVAF: $9.63M vs. IBIO: $37.43M
ELVAF [@Biotechnology] is valued at $9.63M. IBIO’s [@Biotechnology] market capitalization is $37.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVAF’s FA Score shows that 1 FA rating(s) are green whileIBIO’s FA Score has 1 green FA rating(s).

  • ELVAF’s FA Score: 1 green, 4 red.
  • IBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, IBIO is a better buy in the long-term than ELVAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 3 TA indicator(s) are bullish.

  • IBIO’s TA Score: 3 bullish, 6 bearish.

Price Growth

ELVAF (@Biotechnology) experienced а 0.00% price change this week, while IBIO (@Biotechnology) price change was -13.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.29%. For the same industry, the average monthly price growth was -17.13%, and the average quarterly price growth was -18.92%.

Reported Earning Dates

IBIO is expected to report earnings on May 15, 2023.

Industries' Descriptions

@Biotechnology (-11.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBIO($37.4M) has a higher market cap than ELVAF($9.63M). IBIO YTD gains are higher at: 55.102 vs. ELVAF (0.000). ELVAF has higher annual earnings (EBITDA): 1.05M vs. IBIO (-12.84M). IBIO (7.02M) and ELVAF (6.75M) have equal amount of cash in the bank . IBIO has higher revenues than ELVAF: IBIO (375K) vs ELVAF (0).
ELVAFIBIOELVAF / IBIO
Capitalization9.63M37.4M26%
EBITDA1.05M-12.84M-8%
Gain YTD0.00055.102-
P/E RatioN/A2.92-
Revenue0375K-
Total Cash6.75M7.02M96%
Total DebtN/A4M-
FUNDAMENTALS RATINGS
ELVAF vs IBIO: Fundamental Ratings
ELVAF
IBIO
OUTLOOK RATING
1..100
3652
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5199
PRICE GROWTH RATING
1..100
7138
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELVAF's Valuation (20) in the null industry is somewhat better than the same rating for IBIO (57) in the Biotechnology industry. This means that ELVAF’s stock grew somewhat faster than IBIO’s over the last 12 months.

ELVAF's Profit vs Risk Rating (100) in the null industry is in the same range as IBIO (100) in the Biotechnology industry. This means that ELVAF’s stock grew similarly to IBIO’s over the last 12 months.

ELVAF's SMR Rating (51) in the null industry is somewhat better than the same rating for IBIO (99) in the Biotechnology industry. This means that ELVAF’s stock grew somewhat faster than IBIO’s over the last 12 months.

IBIO's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for ELVAF (71) in the null industry. This means that IBIO’s stock grew somewhat faster than ELVAF’s over the last 12 months.

IBIO's P/E Growth Rating (26) in the Biotechnology industry is significantly better than the same rating for ELVAF (100) in the null industry. This means that IBIO’s stock grew significantly faster than ELVAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRAK18.66-0.50
-2.61%
ReposiTrak
ANGI13.10-0.90
-6.43%
Angi Inc
NSC220.74-17.83
-7.47%
Norfolk Southern Corp
NXST166.96-14.90
-8.19%
Nexstar Media Group
SPRO0.62-0.08
-11.61%
Spero Therapeutics

ELVAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVAF has been loosely correlated with REPL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVAF jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVAF
1D Price
Change %
ELVAF100%
N/A
REPL - ELVAF
60%
Loosely correlated
-8.47%
CLYYF - ELVAF
47%
Loosely correlated
N/A
IBIO - ELVAF
39%
Loosely correlated
-7.77%
GLABF - ELVAF
34%
Loosely correlated
N/A
NRSN - ELVAF
24%
Poorly correlated
+3.14%
More

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with ELVAF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
-7.77%
ELVAF - IBIO
39%
Loosely correlated
N/A
REPL - IBIO
38%
Loosely correlated
-8.47%
VOR - IBIO
36%
Loosely correlated
-6.94%
LENZ - IBIO
35%
Loosely correlated
-9.84%
NUVB - IBIO
34%
Loosely correlated
-7.26%
More